Curis (CRIS) Stock Price

Curis Price

NASDAQ·CLOSED
0.61
​
Market closed

Revenue at Curis has contracted by 2.4% per year over the past 19 years to 9.44 M USD. For Curis, the net margin of -80.3% is up versus -426.7% a few years ago.

Curis stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curis business model & stock analysis

Curis Inc generates revenue primarily through the development and potential commercialization of its therapeutic drug candidates in the biotechnology sector. The company focuses on oncology treatments, with its lead candidate Emavusertib targeting IRAK4 kinase inhibition for cancer therapy. Other key products include Erivedge, which inhibits the Hedgehog signaling pathway, and additional candidates like CI-8993, Fimepinostat, CA-170, and CA-327, targeting various cancer-related pathways. The firm conducts R&D internally and via strategic collaborations, aiming to advance these drug candidates toward clinical and commercial stages. Curis Inc's primary buyers are pharmaceutical companies and healthcare institutions seeking innovative cancer treatments. The company's pipeline includes orally available small molecule drugs and monoclonal antibodies designed for targeted cancer therapies. Emavusertib, Erivedge, and CA-170 represent the core product segments, with CA-170 specifically targeting VISTA and PDL1 immune checkpoint proteins. Strategic collaborations support the development of these therapeutics, aligning with the company's focus on oncology drug discovery and development. The company's revenue streams are tied to the progression of its drug candidates through clinical trials and potential partnerships. Emavusertib and Erivedge are in clinical stages, with CA-170 also advancing in development. Curis Inc's business model emphasizes internal R&D alongside strategic alliances to accelerate the development of its pipeline, ensuring that its products reach the market for cancer treatment applications.

Frequently asked questions about Curis

9 analysts currently rate the Curis stock: 8 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Curis share trades at 0.56 EUR (0.61 USD).

The Curis share (CRIS) is listed on 3 stock exchanges, including: NASDAQ (CRIS), Frankfurt (CUS0.F), München (CUS0.MU).

The revenue cannot currently be calculated for Curis.

The expected profit of Curis is -307.43 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Curis is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Curis stock.

The P/S cannot be calculated for Curis currently.

The Eulerpool Quality Score for Curis is 1/10.

The ISIN of Curis is US2312693094. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Curis is A3ETJD. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Curis is CRIS. The ticker symbol is used to trade Curis shares on the stock exchange.

Fair ValueTerminal
0.52 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
185,156.86 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website curis.com
Currency
USD
Initial public offering
Aug 1, 2000
ISIN
US2312693094
Cusip
231269309
Market capitalization
7.94 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-0.00
P/Ee 2027
-0.01
P/Ee 2028
-0.06
P/Ee 2029
-0.09
P/Ee 2030
-1.22
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
1.45
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-107.09 %
Last updated Nov 20, 2026, 3:37 AM

Curis Peer Group

Curis Ticker

FRANKFURT · CUS0.FMUNICH · CUS0.MUNASDAQ · CRIS

Curis FIGI

CRIS:US · BBG000C1GTC9CRIS:UA · BBG000C1GTJ2CRIS:UC · BBG000C1GVD3CRIS:UN · BBG000C1GW14CRIS:UP · BBG000C1GXN8CRIS:UB · BBG000C1GYK9CRIS:UM · BBG000C1GZB6CRIS:UX · BBG000C1GZH0CRIS:UR · BBG000C1GZR9CRIS:UD · BBG000C1H102CRIS:UF · BBG000C1H399CRIS:VY · BBG000C1H3G1

All fundamentals and in-depth analysis of Curis

Our stock analysis for Curis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Curis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.